Opus Genetics, Inc. (IRD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
37000 Grand River Avenue
Durham, MI 48335
United States of America (the)
Phone
248 957 9024
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
January 19, 2015
| Name | Title | Pay | Year Born |
| George Magrath | Chief Executive Officer & Director | 973,790 | 1985 |
| Amy Zaremba Rabourn | Head of Financial Quality Assurance | 434,100 | 1981 |
| Bernhard Hoffmann | Senior Vice President of Corporate Development & Secretary | 434,100 | 1956 |
| Joseph K. Schachle | Chief Operating Officer | 635,920 | 1965 |
| Ashwath Jayagopal | Chief Scientific & Development Officer | 682,360 | 1983 |
| Jenny Kobin | Investor Relations Officer | 0 | N/A |
| Benjamin R. Yerxa | President & Director | 0 | 1966 |
| Sally Tucker | Chief Medical Officer & Senior Vice President of Clinical Development | 0 | N/A |
| Chris Ernst | Chief Technology Officer | 0 | N/A |
| Robert E. Gagnon | Chief Financial Officer & Principal Accounting Officer | 0 | 1974 |
| Bindu Manne | Head of Market Development & Commercialization | 0 | N/A |
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.